Anti-Amyloid 42/40 Antibody, clone W0-2 ZooMAb® Mouse Monoclonal

Кат. номер

ZMS1045-4X25UL

ZMS1045-25UL

ZooMAb antibodies represent an entirely new generation of recombinant monoclonal antibodies.
Each ZooMAb antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb antibodies are reliably available and ready to ship when you need them.
Specificity
Clone W0-2 is a ZooMAb® mouse recombinant monoclonal antibody that detects Amyloid 42/40. It targets an epitope within seven amino acids from the N-terminal region of Amyloid peptide (corresponding to amino acids 672-678 of human amyloid precursor protein).
Linear peptide corresponding to seven amino acids from the N-terminal region of human Amyloid peptide β42/40.
Quality Control Testing
Evaluated by Dot Blot Analysis with synthetic Amyloid 40 peptide.
Dot Blot Analysis (DB): A 1:10,000 dilution of this antibody detected synthetic Amyloid 40, fibrillar oligomer, and A fibrils.
Tested Applications
Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected Amyloid 42/40 in human cerebral cortex and human Alzheimers diseased brain tissue sections.
Immunofluorescence Analysis: A 1:100 dilution from a representative lot detected Amyloid 42/40 in human Alzheimers diseased brain tissue sections.
Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user
Anti-Amyloid 42/40, clone W0-2 ZooMAb®, Cat. No. ZMS1045, is a recombinant Mouse monoclonal antibody that detects Amyloid b42 and 40 and is tested for use in Dot Blot, Immunofluorescence, and Immunohistochemistry (Paraffin).
Target description
Amyloid-beta A4 protein (UniProt: P05067; also known as ABPP, APPI, APP, Alzheimer disease amyloid protein, Amyloid precursor protein, Amyloid-beta precursor protein, Cerebral vascular amyloid peptide, CVAP, PreA4, Protease nexin-II, PN-II) is encoded by the APP (also known as A4, AD1) gene (Gene ID: 351) in human. Deposition of A peptides is an early event in the pathogenesis of Alzheimer s disease (AD) that precedes the formation of Tau-positive paired helical filaments (PHFs) in NFTs. AD is also characterized by a progressive deposition of the A peptide in senile plaques. A peptides originate from the proteolytic cleavage of the amyloid precursor protein (APP). Processing of APP occurs by two major pathways cleavage of APP by a-secretase is a non-amyloidogenic pathway and does not produce A peptides. Cleavage of APP at the N-terminus of the A region by -secretase and at the C-terminus by g-secretase represents the amyloidogenic pathway. The -secretase cleaves APP between residues Met671 and Asp672 and yields sAPP and C99. Following the -secretase cleavage, a second cleavage occurs at the C-terminus of A peptide that releases A from C99. This cleavage occurs in the vicinity of residue 712 of the C-terminus. The g-secretase can cleave the C-terminal region at either Val711 or Ile713 to produce the shorter A peptide (A1-40) or the longer A peptide (A1-42), respectively. The predominant form of A found in the cerebrospinal fluid is the shorter A1-40 peptide. Despite its lower rate of synthesis, A1-42 is the peptide that is initially deposited within the extracellular plaques of AD patients. In addition, A1-42 is more hydrophobic and aggregates at much lower concentration than the A1-40 form. The abnormal accumulation of A peptides can result in neuronal damage and loss by increasing free radical production and activation of inflammatory pathways by enhancing microglial secretion of inflammatory cytokines. Interaction between A and ApoE3 or E4 is also an important determinant of amyloidosis. ApoE3 is shown to inhibit A aggregation in vitro by decreasing A multimers, whereas ApoE4 is reported to accelerate the rate of amyloid fibril formation. This ZooMAb® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals.
Physical form
Purified recombinant mouse monoclonal antibody IgG, lyophilized in PBS, 5% Trehalose, normal appearance a coarse or translucent resin. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.
Reconstitution
300 μg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.
Storage and Stability
Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.
ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Quality Level	200,
biological source	mouse
recombinant	expressed in HEK 293 cells
antibody form	purified antibody
antibody product type	primary antibodies
clone	W0-2, monoclonal, recombinant monoclonal
product line	ZooMAb® learn more,
form	lyophilized
mol wt	calculated mol wt ~ 4.33 kDa, observed mol wt ~4.51 kDa
species reactivity	human
packaging	antibody small pack of 25 µL
enhanced validation	recombinant expression Learn more about Antibody Enhanced Validation,
application(s)	dot blot: suitable, immunofluorescence: suitable, immunohistochemistry (formalin-fixed, paraffin-embedded sections): suitable
isotype	IgG2a
conjugate	unconjugated
shipped in	ambient
storage temp.	2-8°C

WGK Germany	WGK 1
Flash Point F	Not applicable
Flash Point C	Not applicable